Found: 2
Select item for more details and to access through your institution.
Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787).
- Published in:
- 2021
- By:
- Publication type:
- Abstract